FDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product

Moderna wins second product approval with RSV vaccine

Moderna’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved for a disease other than COVID-19.

Moderna notches second product approval with new RSV vaccine

The Cambridge drugmaker has finally succeeded in landing its second product approval from the U.S. Food and Drug Administration after its Covid-19 vaccine.

US FDA approves Moderna’s RSV vaccine, its second marketed product

By Patrick Wingrove (Reuters) – The U.S. Food and Drug Administration has approved Moderna’s respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product. Moderna’s vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. RSV, which produces symptoms similar to a cold but can be fatal for y…

US FDA approves Moderna's RSV vaccine, its second marketed product

The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.